May 2025

Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study

PLoS Med 22(4): e1004591 DOI: org/10.1371/journal.pmed.1004591

Lin et al. compared the risk of CVD in patients with psoriasis who were prescribed biologics or oral therapies and assessed the association between different classes of biologics and CVD risk. Patients with psoriasis-prescribed biologics exhibited a reduced risk of incident CVDs compared with those receiving oral antipsoriatic drugs.

Keywords:

Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis

J Am Acad Dermatol 2025;92:1015-23 DOI: 10.1016/j.jaad.2024.12.025

Chen et al. investigated the risk of MACE and VTE among patients with biologic-naïve psoriasis or PsA receiving biologic therapy. No significant difference in the risks of MACE and VTE was found between new biologics (IL-17i, IL-12/23i, or IL-23i) and TNFi.

Keywords:

March 2025

Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development

Rheumatology (Oxford). 2025;64:1131–1137. doi: 10.1093/rheumatology/keae257

Floris et al. conducted a monocentric cohort study to assess the impact of biologic treatment on the development of PsA in patients with PsO. Treatment with biologics significantly reduced the likelihood of PsA development, with lower prevalence observed across different biologic classes and patterns of joint involvement.

Keywords: